RESUMO
PURPOSE: A shortage of suitable donors is the major impediment to clinical lung transplantation. The rate of lung recovery from potential donors is lower than that for other organs. The purpose of this study was to evaluate what factors could be modified to improve the rate of cadaver lung recovery. METHODS: We performed a retrospective review of records from all thoracic organ donors procured by the California Transplant Donor Network between 1 January 1995 and 31 May 1997 (251 donors) to determine which donor management factors were associated with an increased likelihood of successful lung procurement. RESULTS: There were 88 lung donors (L) and 163 donors from which hearts but no lungs were procured (H). Longer time to donor network referral was associated with a reduced chance for successful lung procurement. Donor age, cause of death, and time of admission were not important factors. Most donors in this study had an acceptable A-a gradient at admission to the hospital but lung function deteriorated in group H. Corticosteroid usage and initially clear breath sounds were independent predictors of successful procurement by multivariate analysis. CONCLUSIONS: Early contact with the donor referral network, and corticosteroids may help to improve the lung procurement rate from potential donors.
Assuntos
Transplante de Pulmão , Doadores de Tecidos , Obtenção de Tecidos e Órgãos/estatística & dados numéricos , Adulto , Cadáver , California , Bases de Dados Factuais , Feminino , Glucocorticoides/uso terapêutico , Humanos , Pulmão/efeitos dos fármacos , Masculino , Hemissuccinato de Metilprednisolona/uso terapêutico , Estudos RetrospectivosRESUMO
BACKGROUND: The number of patients waiting lung transplantation greatly exceeds the supply of donors. This study was conducted to determine the effect of high-dose steroid administration on oxygenation and donor lung recovery after brain death. METHODS: A retrospective analysis was conducted on 118 consecutive organ donors from January 1 through December 31, 1995. Eighty donors received high-dose steroids (methylprednisolone, mean 14.5+/-0.06 mg/kg) after organ procurement organization management began; a second group was composed of 38 patients who received no steroids. PaO2/FiO2 ratios were used to evaluate oxygenation. The number of single and double lungs transplanted served as the endpoint. RESULTS: No differences were noted in hemodynamics, most clinical or demographic variables and initial values of PaO2/FiO2 between groups. However, nonsteroid-treated donors showed an overall decrease in oxygenation (mean decrease in PaO2/FiO2 -34.2+/-14), whereas steroid-treated donors had a significant and progressive increase in oxygenation (mean increase in PaO2/FiO2: 16+/-14) before aortic cross-clamping (p = 0.01). Time before cross-clamping was longer in the steroid-treated patients (p = 0.003). The number of procured lungs was markedly greater in steroid-treated than nonsteroid-treated donors (25/80 patients vs 3/38; p < 0.01). CONCLUSIONS: High-dose methylprednisolone given during donor management results in improved oxygenation at organ recovery. This treatment resulted in a significant increase in the number of lungs transplanted and may have enabled donors to be treated longer.
Assuntos
Morte Encefálica , Glucocorticoides/uso terapêutico , Transplante de Pulmão/métodos , Pulmão/efeitos dos fármacos , Metilprednisolona/uso terapêutico , Consumo de Oxigênio/efeitos dos fármacos , Doadores de Tecidos , Adulto , Aorta/cirurgia , Cadáver , Constrição , Feminino , Glucocorticoides/administração & dosagem , Humanos , Masculino , Metilprednisolona/administração & dosagem , Pessoa de Meia-Idade , Oxigênio/sangue , Estudos Retrospectivos , Fatores de Tempo , Obtenção de Tecidos e ÓrgãosRESUMO
PURPOSE: To determine the toxicities and efficacy of paclitaxel, cyclophosphamide (Cy), and recombinant human granulocyte-colony stimulating factor (filgrastim) administered for mobilization and collection of peripheral blood stem cells (PBSC) in patients with breast and ovarian cancer. METHODS: One hundred and forty-one patients with breast (n = 115) or ovarian cancer (n = 26) received paclitaxel 170 mg/m2 and Cy 2 gm/m2 (n = 42) or paclitaxel 200 mg/m2, Cy 3 gm/m2 (n = 99), and filgrastim (6 micrograms/kg/day) followed by collection of PBSC by apheresis. RESULTS: The 2 dose levels of paclitaxel and Cy tested were well tolerated. The median yield of CD34+ cells from all patients was 6.53 x 10(6)/kg (range, 0.11-51.76) collected with a median of 2 aphereses (range, 1-8). The target dose of 2.5 x 10(6) CD34+ cells/kg was achieved in 85% of patients. The mean daily collection of CD34+ cells was 5.46 x 10(6)/kg for patients receiving 200 mg/m2 of paclitaxel and 3 gm/m2 of Cy as compared to 2.77 for patients receiving the lower doses (p = 0.0005). Increasing the dose of paclitaxel and Cy did not significantly increase the fraction of patients achieving a target dose of 2.5 x 10(6) CD34+ cells/kg (87% vs 81%, p = 0.367) but did increase the fraction achieving a target of 5.0 x 10(6) CD34+ cells/kg (73% vs 45%, p = 0.002). The mean daily collection of CD34+ cells for patients who had received only 1 prior chemotherapy regimen was 6.59 x 10(6)/kg as compared to 3.47 for patients who had received more than 1 prior chemotherapy regimen (p < 0.0001). Prior radiation therapy (p = 0.003) and patient performance status (p = 0.047) were adverse risk factors for achieving a target dose of > or = 2.5 x 10(6) CD34+ cells/kg. CONCLUSIONS: The combination of paclitaxel, Cy, and filgrastim can be administered with acceptable toxicity, allowing collection of adequate quantities of PBSC from the majority of patients with breast and ovarian cancer. Increasing the doses of paclitaxel and Cy increased the number of CD34+ cells collected and decreased the number of apheresis procedures necessary to collect target cell doses. However, increasing drug doses did not increase the fraction of patients yielding the minimum CD34+ target dose of 2.5 x 10(6)/kg. Collection of PBSC early in the disease course is the best strategy to assure optimal CD34+ cell doses in all patients.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Coleta de Amostras Sanguíneas/métodos , Neoplasias da Mama/tratamento farmacológico , Células-Tronco Hematopoéticas/efeitos dos fármacos , Neoplasias Ovarianas/tratamento farmacológico , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias da Mama/sangue , Ciclofosfamida/administração & dosagem , Relação Dose-Resposta a Droga , Feminino , Filgrastim , Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Humanos , Pessoa de Meia-Idade , Neoplasias Ovarianas/sangue , Paclitaxel/administração & dosagem , Proteínas RecombinantesAssuntos
Neoplasias da Mama/patologia , Linfonodos/patologia , Adulto , Fatores Etários , Idoso , Axila , Neoplasias da Mama/terapia , Feminino , Seguimentos , Hospitais Comunitários , Humanos , Metástase Linfática , Mastectomia Radical Modificada , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/epidemiologiaRESUMO
Residue depletion studies were conducted in dairy cattle to monitor morantel-related residues in milk following oral administration of morantel tartrate (Rumate. Eleven lactating cows of various ages, periods of lactation, and known milk production were orally dosed with the bolus formulation of morantel tartrate with an actual dose range of 8.4-9.8 mg/kg body weight. Representative samples of milk were collected at 10-14 h intervals post-dose, and subsamples were assayed for the major and minor hydrolysis products of morantel-related residues, MAPA and CP-20,107. Residues assayed as precursors of MAPA peaked at the second milking (24 h post-dose) and were below 25 ppb (range: less than 12-24 ppb). Precursors of CP-20,107, which confirm the identity of morantel, also peaked at 24 h post-dose (range: 2.1-3.3 ppb) and declined rapidly thereafter. A statistical model was used to project the level of residues at the upper limit of 99% of the total target animal (i.e., dairy cattle) population with 95% confidence. The calculated peak levels from this model were 50 and 5.0 ppb for morantel-related residues convertible to MAPA and CP-20,107, respectively.
Assuntos
Leite/análise , Morantel/análise , Pirimidinas/análise , Animais , Bovinos , Feminino , Cinética , Morantel/análogos & derivadosRESUMO
An improved model was evaluated for determining the efficacy of salinomycin (or other anticoccidials) against severe coccidiosis in floor-pen-reared broiler chickens. Broilers were isolated in wire-floored starting batteries until they were 14 days old, then placed in floor pens and exposed to Eimeria spp. from two sources: litter heavily contaminated with three to eight cycles of coccidia-infected seeder birds, and feed contaminated with oocysts. This procedure resulted in an average mortality rate of 49.3% due to coccidiosis, and evidence of disease was present in all unmedicated birds examined. High lesion scores, depressed weight gains, and poor feed conversion were also observed. Salinomycin, 60 ppm, was efficacious against various mixed species infections in this model.
Assuntos
Galinhas , Coccidiose/tratamento farmacológico , Coccidiostáticos/uso terapêutico , Avaliação Pré-Clínica de Medicamentos/veterinária , Animais , Coccidiose/transmissão , Contaminação de Alimentos , Piranos/uso terapêuticoAssuntos
Galinhas , Coccidiose/veterinária , Coccidiostáticos/uso terapêutico , Furanos/uso terapêutico , Ionóforos/uso terapêutico , Lasalocida/uso terapêutico , Monensin/uso terapêutico , Doenças das Aves Domésticas/prevenção & controle , Animais , Coccidiose/prevenção & controle , Masculino , Piranos/uso terapêuticoAssuntos
Antibacterianos/uso terapêutico , Galinhas , Coccidiose/veterinária , Coccidiostáticos/uso terapêutico , Furanos/uso terapêutico , Lasalocida/uso terapêutico , Monensin/uso terapêutico , Doenças das Aves Domésticas/tratamento farmacológico , Animais , Coccidiose/tratamento farmacológico , Piranos/uso terapêuticoRESUMO
The economic feasibility in 1977 and 1978 of solar water and combined water and space heating is analyzed for single-family detached residences and multi-family apartment buildings in four representative U.S. cities: Boston, Massachusetts; Washington, D.C.; Grand Junction, Colorado; and Los Angeles, California. Three economic decision criteria are utilized: payback period, years to recovery of down payment, and years to net positive cash flow. The cost competitiveness of the solar systems compared to heating systems based on electricity, fuel oil, and natural gas is then discussed for each city, and the impact of the federal tax credit for solar energy systems is assessed. It is found that even without federal incentives some solar water and space heating systems are competitive. Enactment of the solar tax credit, however, greatly enhances their competitiveness. The implications of these findings for government tax and energy pricing policies are discussed.
RESUMO
Salinomycin (Coxistac), a new broad spectrum anticoccidial, was tested in broilers reared in floor pens for safety at 50, 60, 80, 100, and 160 ppm fed continuously from 1 to 56 days of age. Four trials were conducted. Comparisons were made to unmedicated controls and in three trials to monensin to monensin at 80, 100, and 121 ppm. The weight gains at 50 and 60 ppm of salinomycin and 80 and 100 ppm of monensin were statistically comparable and equivalent to or better than controls. The weight gain at 80 ppm of salinomycin was slightly below controls but comparable to 121 ppm monensin. Levels of 100 and 160 ppm of salinomycin depressed weight gain. Feed conversion for all treatments except 160 ppm salinomycin were comparable.